Health
Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the publication of the first peer-reviewed expert recommendations to guide glucocorticoid dose reduction in patients with classic congenital adrenal hyperplasia treated with CRENESSITY® (crinecerfont). Published in The Journal of Clinical Endocrinology & Metabolism, the recommendations address a critical unmet need as real-world use of CRENESSITY expands in both pediatric and adult patients.
About this update from Neurocrine Biosciences, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"New algorithms developed by expert clinical endocrinologists provide clear, practical recommendations for healthcare providers to reduce supraphysiologic glucocorticoid (GC) doses in patients with classic congenital adrenal hyperplasia (CAH) after starting CRENESSITY","length":267,"tagName":"p"}]},{"val":[{"type":"text","content":"CRENESSITY reduces excess androgen production, enabling patients with classic CAH to move toward more physiologic GC dosing while maintaining essential daily cortisol replacement","length":178,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":445,"olType":false},{"type":"text","content":"SAN DIEGO, May 6, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the publication of the first peer-reviewed expert recommendations to guide glucocorticoid dose reduction in patients with classic congenital adrenal hyperplasia treated with CRENESSITY® (crinecerfont). Published in The Journal of Clinical Endocrinology & Metabolism, the recommendations address a critical unmet need as real-world use of CRENESSITY expands in both pediatric and adult patients.","length":497,"tagName":"p"},{"type":"image","alt":"Approach to glucocorticoid reduction with initiation of CRENESSITY in pediatric patients aged four to 17 years with classic CAH*","displaySize":"","headline":null,"caption":"Approach to glucocorticoid reduction with initiation of CRENESSITY in pediatric patients aged four to 17 years with classic CAH*","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":291,"url":"https://media.zenfs.com/en/prnewswire.com/ac5ad590141078ec7095b6bf01715ef3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/VtvNHqmLTbLLH0eOG1caPw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTUxMw--/https://media.zenfs.com/en/prnewswire.com/ac5ad590141078ec7095b6bf01715ef3","width":400,"height":291}},"href":"https://mma.prnewswire.com/media/2973210/Neurocrine_Biosciences_Approach_to_glucocorticoid_reduction_with_initiation_of_CRENESSITY_pediatric.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The recommendations for clinicians treating classic congenital adrenal hyperplasia (CAH) patients with CRENESSITY are presented in two complementary manuscripts — one focused on pediatric patients aged four to 17 years and one focused on ...